Johnson & Johnson (JNJ)
156.73
-1.15
(-0.73%)
USD |
NYSE |
Nov 07, 16:00
156.79
+0.06
(+0.04%)
Pre-Market: 06:36
Johnson & Johnson Revenue (TTM): 87.70B for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 87.70B |
| June 30, 2024 | 86.58B |
| March 31, 2024 | 85.65B |
| December 31, 2023 | 85.16B |
| September 30, 2023 | 83.70B |
| June 30, 2023 | 82.35B |
| March 31, 2023 | 84.85B |
| December 31, 2022 | 87.38B |
| September 30, 2022 | 77.21B |
| June 30, 2022 | 80.55B |
| March 31, 2022 | 79.84B |
| December 31, 2021 | 78.74B |
| September 30, 2021 | 91.45B |
| June 30, 2021 | 89.19B |
| March 31, 2021 | 84.21B |
| December 31, 2020 | 82.58B |
| September 30, 2020 | 80.86B |
| June 30, 2020 | 80.50B |
| March 31, 2020 | 82.73B |
| December 31, 2019 | 82.06B |
| September 30, 2019 | 81.71B |
| June 30, 2019 | 81.32B |
| March 31, 2019 | 81.59B |
| December 31, 2018 | 81.58B |
| September 30, 2018 | 81.38B |
| Date | Value |
|---|---|
| June 30, 2018 | 80.68B |
| March 31, 2018 | 78.69B |
| December 31, 2017 | 76.45B |
| September 30, 2017 | 74.36B |
| June 30, 2017 | 72.53B |
| March 31, 2017 | 72.17B |
| December 31, 2016 | 71.89B |
| September 30, 2016 | 71.60B |
| June 30, 2016 | 70.88B |
| March 31, 2016 | 70.18B |
| December 31, 2015 | 70.07B |
| September 30, 2015 | 70.52B |
| June 30, 2015 | 71.88B |
| March 31, 2015 | 73.59B |
| December 31, 2014 | 74.33B |
| September 30, 2014 | 74.43B |
| June 30, 2014 | 73.54B |
| March 31, 2014 | 71.92B |
| December 31, 2013 | 71.31B |
| September 30, 2013 | 70.52B |
| June 30, 2013 | 69.99B |
| March 31, 2013 | 68.59B |
| December 31, 2012 | 67.22B |
| September 30, 2012 | 65.92B |
| June 30, 2012 | 64.87B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
77.21B
Minimum
Sep 2022
91.45B
Maximum
Sep 2021
83.66B
Average
83.22B
Median
Revenue (TTM) Benchmarks
| Amgen Inc | 32.53B |
| Eli Lilly and Co | 40.86B |
| Merck & Co Inc | 63.17B |
| Pfizer Inc | 59.37B |
| AbbVie Inc | 55.53B |